John Steinharter
Overview
Explore the profile of John Steinharter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
2179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassar A, Abou Alaiwi S, Baca S, Adib E, Corona R, Seo J, et al.
Nat Commun
. 2023 Jan;
14(1):346.
PMID: 36681680
While the mutational and transcriptional landscapes of renal cell carcinoma (RCC) are well-known, the epigenome is poorly understood. We characterize the epigenome of clear cell (ccRCC), papillary (pRCC), and chromophobe...
2.
Wshah S, Xu B, Steinharter J, Reilly C, Morrissette K
J Med Imaging (Bellingham)
. 2022 Oct;
9(5):054502.
PMID: 36186002
Purpose: This is a foundational study in which multiorgan system point of care ultrasound (POCUS) and machine learning (ML) are used to mimic physician management decisions regarding the functional intravascular...
3.
Schmidt A, Tucker M, Bakouny Z, Labaki C, Hsu C, Shyr Y, et al.
JAMA Netw Open
. 2021 Nov;
4(11):e2134330.
PMID: 34767021
Importance: Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in the tissue-based expression of...
4.
Braun D, Street K, Burke K, Cookmeyer D, Denize T, Pedersen C, et al.
Cancer Cell
. 2021 Mar;
39(5):632-648.e8.
PMID: 33711273
The tumor immune microenvironment plays a critical role in cancer progression and response to immunotherapy in clear cell renal cell carcinoma (ccRCC), yet the composition and phenotypic states of immune...
5.
Bi K, He M, Bakouny Z, Kanodia A, Napolitano S, Wu J, et al.
Cancer Cell
. 2021 Mar;
39(5):649-661.e5.
PMID: 33711272
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the...
6.
He M, Cuoco M, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, et al.
Nat Med
. 2021 Mar;
27(3):426-433.
PMID: 33664492
Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors. Cellular programs driving resistance in both cancer...
7.
Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes
Nuzzo P, Berchuck J, Korthauer K, Spisak S, Nassar A, Abou Alaiwi S, et al.
Nat Med
. 2020 Sep;
26(10):1663.
PMID: 32895574
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
8.
Nuzzo P, Berchuck J, Korthauer K, Spisak S, Nassar A, Abou Alaiwi S, et al.
Nat Med
. 2020 Jun;
26(7):1041-1043.
PMID: 32572266
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) is a highly sensitive assay capable of detecting early-stage tumors....
9.
Kuderer N, Choueiri T, Shah D, Shyr Y, Rubinstein S, Rivera D, et al.
Lancet
. 2020 Jun;
395(10241):1907-1918.
PMID: 32473681
Background: Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors...
10.
Braun D, Hou Y, Bakouny Z, Ficial M, Sant Angelo M, Forman J, et al.
Nat Med
. 2020 May;
26(6):909-918.
PMID: 32472114
PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592...